Effect of nandrolone decanoate on serum lipoprotein (a) and its isoforms in hemodialysis patients

Lipids in Health and Disease

Volumn 3, Issue , 2004, Pages

  Ghorbanihaghjo, Amir ^a   Argani, Hassan ^a,b   Rohbaninoubar, Mohammad ^a   Rashtchizadeh, Nadereh ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hemodialysis; Lipoprotein(a); Nandrolone decanoate

Indexed keywords

ALBUMIN; APOLIPOPROTEIN A; CHOLESTEROL; CREATININE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOPROTEIN; LIPOPROTEIN A; NANDROLONE DECANOATE; TRIACYLGLYCEROL;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); CREATININE BLOOD LEVEL; FEMALE; GENETIC TRANSCRIPTION; HEMATOCRIT; HEMATOLOGY; HEMODIALYSIS; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MOLECULAR WEIGHT; MORTALITY; NUTRITIONAL STATUS; PARAMETER; SIDE EFFECT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 13444254099     PISSN: 1476511X     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-3-16     Document Type: Article

References (42)

1. Barton Pai A, Chretien C, Lau AH: The effects of nandrolone decanoate on nutritional parameters in hemodialysis patients. Clin Nephrol 2002, 58:38-46.
2. Johansen KL, Mulligan K, Schambelan M: Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA 1999, 281:1275-1281.
3. Chan CT: Cardiovascular effects of frequent intensive hemodialysis. Semin Dial 2004, 17:99-103.
4. Teruel JL, Lasuncion MA, Rivera M, et al.: Nandrolone decanoate reduces serum lipoprotein(a) concentrations in hemodialysis patients. Am J Kidney Dis 1997, 29:569-575.
5. Navarro JF, Mora-Fernandez C, Rivero A, et al.: Androgens for the treatment of anemia in peritoneal dialysis patients. Adv Perit Dial 1998, 14:232-235.
6. Teruel JL, Aguilera A, Marcen R, Navarro Antolin J, Garcia Otero G, Ortuno J: Androgen therapy for anaemia of chronic renal failure. Indications in the erythropoietin era. Scand J Urol Nephrol 1996, 30:403-408.
7. Johnson CA: Use of androgens in patients with renal failure. Semin Dial 2000, 13:36-39.
8. Kronenberg F, Neyer U, Lhotta K, et al.: The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol 1999, 10:1027-1036.
9. Parsons DS, Reaveley DA, Pavitt DV, Misra M, Brown EA: Lipoprotein(a) levels in those with high molecular weight apo(a) isoforms may remain low in a significant proportion of patients with end-stage renal disease. Nephrol Dial Transplant 2003, 18:1848-1853.
10. Kronenberg F, Lingenhel A, Lhotta K, et al.: The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome. Kidney Int 2004, 65:606-612.
11. Sechi LA, Zingaro L, Catena C, Perin A, De Marchi S, Bartoli E: Lipoprotein(a) and apolipoprotein(a) isoforms and proteinuria in patients with moderate renal failure. Kidney Int 1999, 56:1049-1057.
12. Cauza E, Kletzmaier J, Bodlaj G, Dunky A, Herrmann W, Kostner K: Relationship of non-LDL-bound apo(a), urinary apo(a) fragments and plasma Lp(a) in patients with impaired renal function. Nephrol Dial Transplant 2003, 18:1568-1572.
13. Akaike M, Azuma H, Kagawa A, et al.: Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem 2002, 48:1454-1459.
14. Marcovina SM, Lippi G, Bagatell CJ, Bremner WJ: Testosterone-induced suppression of lipoprotein(a) in normal men; relation to basal lipoprotein(a) level. Atherosclerosis 1996, 122:89-95.
15. Lackner C, Boerwinkle E, Leffert CC, Rahmig T, Hobbs HH: Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulsed-filed gel electrophoresis. J Clin Invest 1991, 87:2153-2161.
16. Kamboh MI, Ferrell RE, Kottke BA: Expressed hypervariable polymorphism of apolipoprotein(a). Am J Hum Genet 1991, 49:1063-1074.
17. MBewu AD, Durrington PN: Lipoprotein(a): structure, properties and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis 1990, 85:1-14.
18. Utermann G: The mysteries of lipoprotein(a). Science 1989, 246:904-910.
19. Klausen IC, Beisiegel U, Menzel HJ, Rosseneu M, Nicaud V, Faergeman O: Apo(a) phenotypes and Lp(a) concentrations in offspring of men with and without myocardial infarction. The EARS Study. European Atherosclerosis Research Study. Arterioscler Thromb Vasc Biol 1995, 15:1001-1008.
20. Linden T, Taddei-Peters W, Wilhelmsen L, et al.: Serum lipids, lipoprotein(a) and apo(a) isoforms in patients with established coronary artery disease and their relation to disease and prognosis after coronary by-pass surgery. Atherosclerosis 1998, 137:175-186.
21. Kronenberg F, Utermann G, Dieplinger H: Lipoprotein(a) in renal disease. Am J kidney Dis 1996, 27:1-25.
22. Rader DJ, Cain W, Zech LA, Usher D, Brewer HB Jr: Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein(a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest 1993, 91:443-447.
23. Tsai YH, Park S, Snook JT: Interaction among Lp(a) phenotypes, Lp(a) concentrations and lipoprotein response to fat-modified diets. J Nutr Biochem 1998, 9:106-113.
24. Gaubatz JW, Ghanem KI, Guevara J Jr, Nava ML, Patsch W, Morrisett JD: Polymorphic forms of human apolipoprotein[a]: inheritance and relationship of their molecular weights to plasma levels of lipoprotein[a]. J Lipid Res 1990, 31:603-613.
25. Milionis HJ, Elisaf MS, Tselepis A, Bairaktari E, Karabina SA, Siamopoulos KC: Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failure. Am J Kidney Dis 1999, 33:1100-1106.
26. Kandoussi AM, Hugue V, Cachera C, et al.: Apo(a) phenotypes and Lp(a) concentrations in renal transplant patients. Nephron 1998, 80:183-187.
27. Rainwater DL: Lp(a) concentrations are related to plasma lipid concentrations. Atherosclerosis 1996, 127:13-18.
28. Nestel P, Noakes M, Belling B, et al: Plasma lipoprotein lipid and Lp(a) changes with substitution of elaidic acid for oleic acid in the diet. J lipid Res 1992, 33:1029-1036.
29. Mensink RP, Zock PL, Katan MB, Hornstra G: Effect of dietary cis and trans fatty acids on serum lipoprotein[a] levels in humans. J lipid Res 1992, 33:1493-1501.
30. Hunninghake DB, Stein EA, Mellies MJ: Effects of one year of treatment with pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein a. J Clin Pharmacol 1993, 33:574-580.
31. Leren TP, Hjermann I, Berg K, Leren P, Foss OP, Viksmoen L: Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia. Atherosclerosis 1988, 73:135-141.
32. Haffner S, Orchard T, Stein E, Schmidt D, LaBelle P: Effect of simvastatin on Lp(a) concentrations. Clin Cardiol 1995, 18:261-267.
33. Monte G, Mezdour H: The pharmacological effects of certain compounds on lipoprotein(a). Recenti Prog Med 1993, 84:855-863.
34. Navarro JF: In the erythropoietin era, can we forget alternative or adjunctive therapies for renal anaemia management? The androgen example. Nephrol Dial Transplant 2003, 18:2222-2226.
35. Teruel JL, Marcen R, Navarro JF, et al: Evolution of serum erythropoietin after androgen administration to hemodialysis patients: a prospective study. Nephron 1995, 70:282-286.
36. Gonbert S, Malinsky S, Sposito AC, et al.: Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis 2002, 164:305-311.
37. Scanu AM: Lp(a) lipoprotein-coping with heterogeneity. N Engl J Med 2003, 349:2089-2090.
38. Rader DJ, Cain W, Ikewaki K, et al.: The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest 1994, 93:2758-2763.
39. Brunner C, Lobentanz EM, Petho-Schramm A, et al.: The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells. J Biol Chem 1996, 271:32403-32410.
40. Kronenberg F, Utermann G, Dieplinger H: Lipoprotein(a) in renal disease. Am J Kidney Dis 1996, 27:1-25.
41. Rader DJ, Cain W, Zech LA, Usher D, Brewer HB Jr: Variation in lipoprotein(a) concentration among individuals with the same apolipoprotein(a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest 1993, 91:443-447.
42. Martin S, Ladona MG, Pedro-Botet J, Covas MI, Rubies-Prat J: Differential expression of double-band apolipoprotein(a) phenotypes in healthy Spanish subjects detected by SDS-agarose immunoblotting. Clin Chim Acta 1998, 277:191-205.